PD59-09 EXTENDED ANTICOAGULATION AFTER RADICAL CYSTECTOMY: A SINGLE-INSTITUTIONAL EXPERIENCE

You have accessJournal of UrologyBladder Cancer: Invasive V (PD59)1 Sep 2021PD59-09 EXTENDED ANTICOAGULATION AFTER RADICAL CYSTECTOMY: A SINGLE-INSTITUTIONAL EXPERIENCE Kassem Faraj, Derek Scott, Rohan Singh, and Mark Tyson FarajKassem Faraj More articles by this author , ScottDerek Scott SinghRohan Singh TysonMark View All Author Informationhttps://doi.org/10.1097/JU.0000000000002096.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Extended anticoagulation therapy has been found be effective in reducing the risk developing venous thromboembolism (VTE) trials evaluating major oncological surgeries. This practice not universally adopted care patients undergoing radical cystectomy. At our institution, we modified extended options low-dose oral options. study aims report experience with VTE prophylaxis at time RC. METHODS: is a retrospective review that included all who underwent RC institution between 01/2007-06/2020. Exclusion criteria following: prior history VTE, those on surgery, thrombosis events after 90 days, for benign indication, non-bladder indication. was continued 30 days surgery either daily 40 mg subcutaneous enoxaparin, 10 rivaroxaban, or 2.5 apixaban twice per day. Descriptive statistics were performed evaluate characteristics developed symptomatic verses did not. We then multivariable logistics regression analysis identify factors associated development VTE. RESULTS: In 616 patients, median age 72 years, medium BMI 28. Seventy-four received some form prophylaxis. On descriptive analysis, deep vein (DVT) less common cohort, though statistically significant (1.4% vs 5.4%, p=0.132). The incidence pulmonary embolism similar cohorts (2.7% 3.2%, p=0.834). Of 74 prophylaxis, 15 (20.2%) 9 (12.2%) rivaroxaban Eliquis, respectively. gastrointestinal bleed low entire cohort no DVT group bleed, compared 1.5 % control (p=0.376). reduced approached statistical significance (OR 0.32, p=0.08). CONCLUSIONS: VT Oral anticoagulant are just as safe appear rates larger studies needed confirm these results. Source Funding: generously supported funding from Robert D. Patricia E. Kern Center Health Care Delivery Science, Christian Haub Family Career Development Award Cancer Research Honoring Dr Richard Emslander, Eric Gail Blodgett Foundation. sponsors involved design; collection, interpretation data; writing report; decision submit article publication. © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1057-e1057 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...